Renalytix PLC
LSE:RENX
Intrinsic Value
Renalytix Plc manufactures medical devices and equipment. [ Read More ]
The intrinsic value of one RENX stock under the Base Case scenario is 40.61 GBX. Compared to the current market price of 33.5 GBX, Renalytix PLC is Undervalued by 18%.
Valuation Backtest
Renalytix PLC
Run backtest to discover the historical profit from buying and selling RENX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Renalytix PLC's business.
What risks and challenges
does Renalytix PLC face in the near future?
Summarize the latest earnings report
of Renalytix PLC.
Provide P/E
for Renalytix PLC and its competitors.
Balance Sheet Decomposition
Renalytix PLC
Current Assets | 28.3m |
Cash & Short-Term Investments | 26.3m |
Receivables | 776k |
Other Current Assets | 1.3m |
Non-Current Assets | 13.8m |
PP&E | 1.2m |
Intangibles | 12.5m |
Other Non-Current Assets | 51k |
Current Liabilities | 16.1m |
Accounts Payable | 2.9m |
Accrued Liabilities | 8.6m |
Other Current Liabilities | 4.6m |
Non-Current Liabilities | 7.5m |
Long-Term Debt | 7.5m |
Earnings Waterfall
Renalytix PLC
Revenue
|
3.4m
USD
|
Cost of Revenue
|
-2.7m
USD
|
Gross Profit
|
701k
USD
|
Operating Expenses
|
-43.1m
USD
|
Operating Income
|
-42.4m
USD
|
Other Expenses
|
-3.9m
USD
|
Net Income
|
-46.2m
USD
|
Free Cash Flow Analysis
Renalytix PLC
What is Free Cash Flow?
RENX Profitability Score
Profitability Due Diligence
Renalytix PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Renalytix PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
RENX Solvency Score
Solvency Due Diligence
Renalytix PLC's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Renalytix PLC's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RENX Price Targets Summary
Renalytix PLC
According to Wall Street analysts, the average 1-year price target for RENX is 143.14 GBX with a low forecast of 87.87 GBX and a high forecast of 220.5 GBX.
Shareholder Return
RENX Price
Renalytix PLC
Average Annual Return | 33.04% |
Standard Deviation of Annual Returns | 100.26% |
Max Drawdown | -99% |
Market Capitalization | 31.4m GBX |
Shares Outstanding | 99 930 100 |
Percentage of Shares Shorted | 205% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
Contact
IPO
Employees
Officers
The intrinsic value of one RENX stock under the Base Case scenario is 40.61 GBX.
Compared to the current market price of 33.5 GBX, Renalytix PLC is Undervalued by 18%.